BIOVECTRA is honored with 2025 CDMO Management Award for biologics

BIOVECTRA, part of Agilent Applied sciences Inc., is a number one North American CDMO specializing in biologics, mRNA therapeutics, and complicated chemistry, proudly declares it’s the recipient of the 2025 Outsourced Pharma CDMO Management Award within the class of biologics. The award acknowledges BIOVECTRA’s efficiency in key areas comparable to high quality, reliability, and technical functionality.

“We’re thrilled to introduce our 2025 CDMO Management Awards winners to the outsourcing neighborhood and honored to supply such an vital instrument for drug sponsors in choosing their best-fit companion to assist carry life-saving therapies to market,” stated Louis Garguilo, chief editor at Outsourced Pharma. “The brand new classes and enhanced scoring methodology that went into this yr’s appraisal carry an improved expertise for drug sponsors utilizing the useful resource in addition to an ever-so-coveted distinction for the CDMOs. The disclosing of the award champions throughout our celebration in March might be an thrilling new addition to the festivities.”

For the final fourteen years, the CDMO Management Awards have acknowledged top-performing contract improvement and manufacturing organizations based mostly on business analysis and sponsor suggestions and affords drug builders perception into extremely rated outsourcing companions.

This award is a testomony to BIOVECTRA / Agilent’s deep dedication to a client-first strategy rooted in scientific excellence and manufacturing options,”

Brian Carothers, Vice President and Common Supervisor, Superior Manufacturing Partnerships Division, Agilent Applied sciences

“We’re honored that our group’s dedication to advancing biologics manufacturing and setting new requirements is being acknowledged amongst business leaders. From course of improvement by means of to commercial-scale manufacturing, we stay targeted on delivering high-quality biomanufacturing options that help accelerating our purchasers’ path to market.”

BIOVECTRA will rejoice this achievement alongside fellow award recipients on the CDMO Management Awards ceremony in New York Metropolis on March 19, 2025.

BIOVECTRA helps purchasers throughout the biologics provide chain with superior capabilities and experience in microbial fermentation, protein purification, and single-use bioprocessing applied sciences. Its GMP-certified services present clinical-to-commercial scale manufacturing, together with aseptic fill end capabilities for injectable therapies. The corporate’s funding in superior biomanufacturing applied sciences and versatile manufacturing infrastructure allow drug sponsors to streamline improvement timelines whereas sustaining regulatory compliance.